Omega-3 Fatty Acids for Lupus (SLE)

Omega-3 fatty acids from fish oil have been tested in systemic lupus erythematosus (SLE) since the late 1980s, always as an add-on to usual care. The pooled answer is a small benefit: a 2020 meta-analysis of five randomised trials (274 adults) found omega-3 reduced disease activity by about 0.9 points on the SLEDAI scale, the standard lupus activity score, but graded the certainty of that evidence as low [1].

The individual trials disagree. Two trials with overlapping authors found clear improvements at 3 g a day of omega-3 or fish oil [2][3], while a 12-week trial of prescription omega-3 in 85 adults [4] and a 24-week trial of krill oil in 78 adults [5] found no change in disease activity overall. Our verdict is mixed, with limited evidence: most trials enrolled fewer than 90 people, and the meta-analysis itself rated its certainty low. For the rest of the lupus picture, see the vitamin D and DHEA pages.

EPA and DHA, the long-chain omega-3s in fish oil, are taken up into cell membranes at the expense of arachidonic acid, an omega-6 fat. In 12 people with lupus nephritis, fish oil raised platelet EPA six- to fifteen-fold, cut platelet arachidonic acid incorporation by 16-20% and reduced neutrophil leukotriene B4 release by up to 78% [6].

In the 2024 krill oil trial, participants started low: the average red blood cell Omega-3 Index was 4.43% at baseline, and supplementation raised it to 8.05% by 24 weeks [5]. Trials have also reported lower CRP [7], lower ESR [8] and reduced platelet oxidative stress markers [2] with omega-3.

Changing a blood fat profile is not the same as calming lupus. In the same early study, fish oil had no effect on immune complexes, anti-DNA antibodies or albuminuria [6], and a systematic review found no benefit on complement (C3, C4) or anti-dsDNA across trials [9]. The krill oil trial corrected omega-3 status in nearly everyone but changed disease activity only in a small high-activity subgroup [5].

One genetic study points the other way: people whose genes predict higher circulating omega-3 had a modestly higher risk of developing SLE (odds ratio 1.49) [10]. That is an association about getting lupus, not a test of supplements in people who already have it, but it is a reason not to assume more is always better.

The meta-analysed trials all used 3 g a day of omega-3 or less, for 12 to 52 weeks [1]. The two positive 24-week trials gave 3 g a day of omega-3 [2] or of a fish oil product [3]; the null 2013 trial gave 3 g a day of a prescription omega-3 for 12 weeks [4]; a pilot in 49 women used 1080 mg EPA plus 200 mg DHA [7]; and the 2024 trial used 4 g a day of krill oil concentrate [5]. Early crossover trials used 15-20 g a day [11][19], doses nobody should copy.

Labels matter: "3 g of fish oil" and "3 g of omega-3" are different amounts, so read the EPA plus DHA content per capsule. For context, the European Food Safety Authority considers combined EPA and DHA intakes up to about 5 g a day safe long term [13]. Changes in the Omega-3 Index appeared within 4 weeks [5], but trials judged clinical effects at 3-6 months, and one early benefit had faded by 6 months [12].

The 2020 meta-analysis combined five randomised trials with 274 adults, mostly women with an average age of 43, followed for 12 to 52 weeks. Omega-3 lowered disease activity with a standardised mean difference of -0.33 (95% CI -0.57 to -0.09), equal to about 0.9 SLEDAI points, with no heterogeneity between trials; the authors graded the certainty as low [1].

A 2022 systematic review of 13 articles found that eight of the ten trials measuring disease activity reported some improvement, but no trial showed benefit on kidney measures, complement or anti-dsDNA [9]. Its search ended in April 2021, before the nephritis trial described below.

In a 24-week double-blind trial in 60 adults, the group taking 3 g a day of omega-3 saw its SLAM-R activity score fall from 9.4 to 6.3 and BILAG from 13.6 to 6.7 (both p<0.001), and blood vessel function improve (flow-mediated dilation from 3.0% to 8.9%) [2]. These are changes within the fish oil group; the abstract does not report the comparison with placebo. An earlier factorial trial from the same group in 52 patients found SLAM-R fell from 6.12 to 4.69 with fish oil versus placebo (p<0.05), while copper did nothing [3].

In 50 outpatients over 6 months, fish oil improved the physician's global assessment versus olive oil (p=0.015) [8]. An early crossover trial combined 20 g a day of fish oil with a low-fat diet: of 17 patients who completed 34 weeks, 14 reached useful or ideal status on fish oil [19]. In lupus nephritis, a 2021 trial in 237 patients reported complete remission in 46.9% with fish oil added to cyclophosphamide versus 32.6% with placebo, and fewer infections [14]; that abstract gives no dose or duration, and the result has not been replicated.

The two largest trials of overall disease activity were null. In 85 adults given 3 g a day of prescription omega-3 for 12 weeks, there was no difference in blood vessel function, disease activity or inflammatory markers [4]. In 78 adults given 4 g a day of krill oil for 24 weeks, SLEDAI-2K did not change overall; scores fell only in those with high baseline activity, a subgroup of 9 patients per arm [5].

The same 6-month fish oil trial that improved the physician's rating found no difference in fatigue scores (p=0.350) or SLEDAI (p=0.417), only a non-significant trend on the SF-36 energy/fatigue score (p=0.092) [8]. A one-year crossover trial at 15 g a day in stable lupus nephritis found no effect on kidney function or disease activity [11], and a small crossover trial found that a 3-month benefit had disappeared by 6 months [12].

No trial has been large or long enough to show fewer flares, less organ damage or lower steroid needs. Most enrolled fewer than 90 people, several had high dropout (only 32 of 50 completed one trial [8]), and the most positive results come from one research group. The large VITAL trial of 1000 mg a day in 25,871 older adults did not significantly reduce new autoimmune disease overall (hazard ratio 0.85, 95% CI 0.67 to 1.08) and did not test lupus treatment [15].

Standard care is where the strong evidence sits. The 2023 EULAR recommendations advise hydroxychloroquine for everyone with lupus, keeping maintenance steroids at 5 mg a day of prednisone or less, and adding immunosuppressants or biologics such as belimumab or anifrolumab to control disease [18]. Omega-3 belongs, at most, alongside that plan.

The lupus trials reported omega-3 as well tolerated, including 4 g a day of krill oil over 24 weeks [5]. Common side effects of omega-3 supplements are usually mild: unpleasant taste, bad breath, heartburn, nausea, stomach upset and diarrhoea [13]. In one trial LDL cholesterol rose 3.11 mg/dL on omega-3 versus a 1.87 mg/dL fall on placebo [4].

Two risks matter more. Across large cardiovascular trials, omega-3 supplements raised the risk of atrial fibrillation (hazard ratio 1.25), more so above 1 g a day (hazard ratio 1.49) [16]. Bleeding risk was not raised overall in a meta-analysis of 120,643 patients, though high-dose purified EPA carried a small extra absolute risk of about 0.6% [17]. The prescription omega-3 label advises caution in people allergic to fish or shellfish, says it is not known whether the medicine can harm an unborn baby, and notes it can pass into breast milk [20].

Omega-3 has few drug interactions, but the ones that exist touch medicines common in lupus. Most research finds 3-6 g a day of fish oil does not significantly change anticoagulation on warfarin, though individual INR rises have been reported [13]. Background antiplatelet use did not change bleeding risk in the large meta-analysis [17], and the nephritis trial combined fish oil with prednisone and cyclophosphamide without reported harm [14].